Cargando…

β(3)-Adrenoceptor redistribution impairs NO/cGMP/PDE2 signalling in failing cardiomyocytes

Cardiomyocyte β(3)-adrenoceptors (β(3)-ARs) coupled to soluble guanylyl cyclase (sGC)-dependent production of the second messenger 3’,5’-cyclic guanosine monophosphate (cGMP) have been shown to protect from heart failure. However, the exact localization of these receptors to fine membrane structures...

Descripción completa

Detalles Bibliográficos
Autores principales: Schobesberger, Sophie, Wright, Peter T, Poulet, Claire, Sanchez Alonso Mardones, Jose L, Mansfield, Catherine, Friebe, Andreas, Harding, Sian E, Balligand, Jean-Luc, Nikolaev, Viacheslav O, Gorelik, Julia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138611/
https://www.ncbi.nlm.nih.gov/pubmed/32228862
http://dx.doi.org/10.7554/eLife.52221
Descripción
Sumario:Cardiomyocyte β(3)-adrenoceptors (β(3)-ARs) coupled to soluble guanylyl cyclase (sGC)-dependent production of the second messenger 3’,5’-cyclic guanosine monophosphate (cGMP) have been shown to protect from heart failure. However, the exact localization of these receptors to fine membrane structures and subcellular compartmentation of β(3)-AR/cGMP signals underpinning this protection in health and disease remain elusive. Here, we used a Förster Resonance Energy Transfer (FRET)-based cGMP biosensor combined with scanning ion conductance microscopy (SICM) to show that functional β(3)-ARs are mostly confined to the T-tubules of healthy rat cardiomyocytes. Heart failure, induced via myocardial infarction, causes a decrease of the cGMP levels generated by these receptors and a change of subcellular cGMP compartmentation. Furthermore, attenuated cGMP signals led to impaired phosphodiesterase two dependent negative cGMP-to-cAMP cross-talk. In conclusion, topographic and functional reorganization of the β(3)-AR/cGMP signalosome happens in heart failure and should be considered when designing new therapies acting via this receptor.